GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00532610
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
- Conditions
- Osteoporosis
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00532077
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: GSK716155 for injectionDrug: Placebo
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00530309
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00530790
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 759
- Registration Number
- NCT00529568
- Locations
- 🇺🇦
GSK Investigational Site, Vinnitsa, Ukraine
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
- Conditions
- Influenza
- Interventions
- Biological: GSK Biologicals Influenza Vaccine GSK576389ABiological: Fluarix
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1252
- Registration Number
- NCT00529516
- Locations
- 🇳🇴
GSK Investigational Site, Skien, Norway
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00528281
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 214
- Registration Number
- NCT00527826
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaProstatic Hyperplasia
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 253
- Registration Number
- NCT00527605
- Locations
- 🇨🇳
GSK Investigational Site, Tianjin, China
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
- Conditions
- Neoplasms, Gastrointestinal Tract
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT00526669
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan